Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
metoclopramide or mosapride
The First People's Hospital of Lianyungang
Severe Stroke
1 trial -
mitomycin C
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obstructive Airway Disease
1 trial -
modified BEAM
The First People's Hospital of Lianyungang
Autologous Stem Cell Transplantation
1 trial -
morphine
Hospital Authority, Hong Kong
Pain Postoperative
1 trial -
multi-intervention program and protein foods supplementation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcopenia
1 trial -
multi-vitamin carbohydrate
The First People's Hospital of Lianyungang
Nausea and Vomiting, Aspiration, Intraoperative
1 trial -
n-3 Polyunsaturated fatty acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Diseases
1 trial -
nutrition treat
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Crohn's Disease
1 trial -
omega-3 polyunsaturated fatty acids
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Type 2 Diabetes Mellitus
1 trial -
only antiemetic (Ramosetron, Tropisetron and dexamethasone)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chemotherapy-induced Nausea and Vomiting
1 trial -
oral nutritional supplement
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
oxycodone and parecoxib sodium combinations
The First People's Hospital of Lianyungang
Oxycodone
1 trial -
oxygen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sepsis
1 trial -
oxytocin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Interoception
1 trial -
oxytocin treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy
1 trial -
parecoxib
The First People's Hospital of Lianyungang
Pain, Postoperative
1 trial -
parecoxib
The First People's Hospital of Lianyungang
Anti-Inflammatory Agents, Non-Steroidal
1 trial -
placebo (compared to vasoconstrictor)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy Adult Male
1 trial -
plasmalyte solution
Hospital Authority, Hong Kong
Cardiac Surgery
1 trial -
postbiotics
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ADHD - Attention Deficit Disorder With Hyperactivity
1 trial -
postoperative adjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Small-cell Lung Cancer
1 trial -
pre-packaged low-residue diet for bowel preparation
The First People's Hospital of Lianyungang
IBD (Inflammatory Bowel Disease)
1 trial -
pre-packaged low-residue diet for bowel preparation
The First People's Hospital of Lianyungang
Colonoscopy: Bowel Preparation
1 trial -
preoperative oral carbohydrate drink
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources